Squamous lung cancer, as a type of lung cancer, has fewer targeted drugs in the clinical treatment process compared to adenocarcinoma. The general clinical treatment strategy is based on chemotherapy, which is the conventional treatment for squamous lung cancer. There are many studies on the treatment of squamous lung cancer with albumin paclitaxel, which has obvious therapeutic effect. For albumin paclitaxel, the characteristics of the drug itself are not only the anti-tumor characteristics of paclitaxel, but also can well reduce the toxic and allergic reactions. Albumin paclitaxel itself is a humanized albumin with better solubility and lower rate of allergic reactions compared with paclitaxel. Other studies have reported its adverse effects on myelosuppression, fluid retention, etc., all relatively less than other paclitaxel. Albumin paclitaxel has also shown good performance in the treatment of squamous carcinoma, which can alleviate the patient’s disease or improve the patient’s survival time and quality of life. Some patients have significant advantages over other chemotherapy regimens. When there is resistance or intolerance to re-chemotherapy, paclitaxel can be an important treatment alternative for patients with squamous carcinoma. Squamous cancer treatment options such as etoposide are not very effective, and etoposide adverse effects may be intolerable for some patients.